Pfizer

Pfizer announced positive Phase 3 TALAPRO-2 trial results for TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in treating metastatic castration-resistant...

The global conventional and alternative pain treatment market, valued at $96.2 billion in 2024, is projected to reach $144.2...

Atavistik Bio and Pfizer have partnered to discover novel allosteric therapeutics for two undisclosed targets chosen by Pfizer. Atavistik...

Pfizer has appointed Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development,...

Pfizer recently received approval from the U.S. Food and Drug Administration (FDA) for ABRYSVO®, its respiratory syncytial virus (RSV)...

Pfizer has voluntarily withdrawn OXBRYTA (voxelotor) from all markets due to an imbalance in vaso-occlusive crises and fatal events...

The U.S. Food and Drug Administration (FDA) has approved Pfizer and BioNTech’s Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine for...

Pfizer and BioNTech have released preliminary findings from a Phase 3 clinical trial evaluating their mRNA vaccine candidate that...

Pfizer has reported positive results from a clinical trial evaluating its vaccine, ABRYSVO, in immunocompromised adults at risk of...

The AFFINE study evaluating giroctocogene fitelparvovec, a gene therapy for moderate to severe hemophilia A, has achieved significant results....